Albert S Khouri, MD
Dr Khouri is an academic glaucoma specialist serving patients in NJ and NY. As a glaucoma specialist Dr Khouri has expertise in the medical and surgical treatments of glaucoma.
Dr Khouri is the Director of Glaucoma at Rutgers University and is an Associate Professor at New Jersey Medical School. He oversees Resident Education as Program Director of the only Ophthalmology training program in New Jersey. Dr Khouri also co-directs the Ophthalmology Telemedicine community outreach program.
Dr Albert Khouri provides consultative glaucoma services at The Institute of Ophthalmology and Visual Science at Rutgers with offices in Roseland and Newark, NJ. Dr Khouri's expertise is in the medical, laser, and surgical treatments of glaucoma including Minimally Invasive Glaucoma Surgery (MIGS) like the iSTENT micro-shunt, iStent inject, XEN Gel implant, and KDB Goniotomy.
The glaucoma service provides specialized glaucoma care for patients with complex eye diseases through collaborations with colleagues at the largest university academic referral practice in New Jersey (The Institute of Ophthalmology & Visual Science includes faculty teams that are specialized in collaborative care of patients with glaucoma, retina, cornea, uvietis, neuro-ophthalmology, and pediatric eye diseases).
New Jersey's largest multidisciplinary academic university based ophthalmic consultant group- Glaucoma, Retina, Cornea, Plastics, Pediatric Ophthalmology, neuro-ophthalmology
Glaucoma Diagnostic Laboratory
Center for Clinical Trials & Research
International Congress- University of Cairo 2016
Select reports by Dr Albert Khouri on glaucoma surgery
Scientific papers published by Dr Albert Khouri in US and International journals.
More than 50 peer-reviewed papers and 150 scientific abstracts
Glaucoma Research Center
Glaucoma novel medications FDA Trials
Glaucoma new drug delivery systems
Glaucoma Imaging and software filters
Dr Khouri chairs the course on managing the challenges of uveitic glaucoma with national and international ophthalmology experts, (Drs Chu, Ghate-USA, Lai-Hong Kong) Chicago, Oct 2016
MIGS surgery course, Chicago 2018
Glaucoma Subspecialty Day Faculty, 2018
Leadership Development Program, 2018
Presented on additivity of fixed combination to prostaglandins therapy, CA 2017
Glaucoma tube shunt surgery, NY 2018
MIGS after glaucoma lasers, San Francisco, 2019
The first Telemedicine Glaucoma symposium included Drs Khouri, Pasquale and Song (USA), Damji (Canada), Czech Republic, June 2016
Dr Khouri chairs a scientific course with Drs from Singapore, UK and the USA on resident performed glaucoma surgery, Hong Kong, 2015.
Symposium on glaucoma surgery, Helsinki, Finland 2017
Wet Lab instruction in Minimally Invasive Glaucoma Surgery, Finland 2017
Functional testing for glaucoma, Melbourne, Australia, 2019
Annual meeting co-sponsored with the state society leadership on advocacy and advancement of Ophthalmology in New Jersey. Dr Khouri serves on the Board of the NJ Ophthalmology Society
Nominated to the American Academy of Ophthalmology Leadership Development Program, 2018
Vice President New Jersey Academy of Ophthalmology 2019
More than 100 scientific research abstracts and presentations (glaucoma surgery, laser treatment, diagnostics and imaging, resident education, Telemedicine and Teleglaucoma- among other contibutions). Dr Khouri mentors medical students and resident physicians in glaucoma research- Seattle, 2014, Denver, 2015, Chicago 2016, Baltimore, 2017, Hawaii 2018, Vancouver, 2019
Symposia on optic nerve imaging, Tele-Glaucoma, glaucoma filtering surgery and management of glaucoma surgical complications, Oman 2016.
Long term efficacy of Microinvasive Glaucoma Surgery, Montreal 2018
Resident education at New Jersey Medical School
Teaching: Dr Khouri serves as the director of resident education at the Institute of Ophthalmology & Visual Science. Dr Khouri is an active member of the American Academy of Ophthalmology and the World Glaucoma Association and chairs educational activities at national and international scientific meetings.
Research: Together with a team of researchers Dr Khouri supervises innovative glaucoma and telemedicine research with medical students and research associates. Ongoing research at Dr Khouri's Glaucoma Lab focuses on improving outcomes of treatments for glaucoma as well as studying new classes of medications, and novel drug delivery methods. Translational research in imaging aims at improving detection of glaucoma during ocular screening and tele-Glaucoma.
Once-daily netarsudil 0.02% vs twice-daily timolol maleate 0.5% in ocular hypertension or open-angle glaucoma, the ROCKET-4 study
Albert Khouri, MD, Newark, NJ
Jason Bacharach, MD, North Bay Eye Associates, Inc., Petaluma, CA, United States
Richard A. Lewis, MD, Sacramento Eye Consultants, Sacramento, CA, United States
Dale Usner, PhD
Puiwah Braswell, PMP, Aerie Pharmaceuticals, Inc., Irvine, CA, United States
Nancy Ramirez, MS, Bedminster, New Jersey
Casey Kopczynski, PhD, Aerie Pharmaceuticals, Durham, NC, United States
Theresa GH. Heah, MD, Aerie Pharmaceuticals, Bedminster, NJ, United States
Purpose/Relevance:
Netarsudil, a ROCK/NET inhibitor, lowers intraocular pressure (IOP) primarily by increasing trabecular outflow.1 In prior phase 3 trials, once-daily (QD) netarsudil 0.02% exhibited clinically significant IOP lowering in patients with elevated IOP.2 We summarize 6-month data from the phase 3 ROCKET-4 study.
Methods:
ROCKET-4 (NCT02558374) was a double-masked, randomized trial in patients with unmedicated IOP >20 and <30 mmHg at 8:00 AM and >17 and <30 mmHg at 10:00 AM and 4:00 PM administered QD (PM) netarsudil 0.02% or twice-daily (BID) timolol maleate 0.5% for 6 months. Mean IOP was measured at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and months 3–6. The primary efficacy endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3 in patients with baseline IOP <25 mmHg (per-protocol population). Adverse events (AEs) were recorded to month 6.
Results:
In total, 186 patients from each arm were included in the primary analysis at baseline. Mean baseline IOP in the primary efficacy population was similar between treatment arms. QD netarsudil met the primary endpoint of noninferiority to BID timolol at all time points up to month 3; mean diurnal IOP through month 3 was 16.8–17.2 mmHg for netarsudil and 16.9–17.1 mmHg for timolol. The IOP-lowering efficacy of QD netarsudil remained within the noninferiority range of BID timolol at all time points over months 4–6. Noninferiority was also seen in patients with baseline IOP <27 mmHg or <30 mmHg. The most frequent AE was conjunctival hyperemia, which was reported in 48% of netarsudil-treated patients and graded as mild in 77% of those affected. Other ocular AEs in ROCKET-4 were comparable to those reported in prior netarsudil trials.2 No treatment-related serious AE was reported for netarsudil. Significant reductions in mean heart rate of up to 3 bpm were seen for timolol (p<0.0001).
Discussion:
In ROCKET-4, QD netarsudil was noninferior to BID timolol in patients with baseline IOP <25 mmHg over 3 months (primary analysis). In this final analysis, netarsudil demonstrated a consistent level of IOP lowering across all baseline IOPs that was durable over 6 months.
Conclusion:
QD netarsudil has demonstrated consistent and sustained IOP lowering in 3 phase 3 trials, with tolerable ocular safety.
556 Eagle Rock Ave, Suite 206
Roseland, NJ 07068
Newark Offices
Rutgers Doctors Office Center
Institute of Ophthalmology & Visual Science
90 Bergen St, Suite 6100
Newark, NJ 07103
Monday - Friday: 8am - 5pm
Saturday: Closed
Sunday: Closed
Incisional Glaucoma Surgery
Expertise in the repair of glaucoma related complications. In this case- a glaucoma drain is exposed predisposing a patient to unacceptable risks of infection. The area is repaired using eye bank cornea tissue.
Expertise in the repair of glaucoma related complications. In this case- a glaucoma drain is exposed predisposing a patient to unacceptable risks of infection. The area is repaired using eye bank cornea tissue.